A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
150actual
Sites
15
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-22 | actual | When the study began enrolling |
| Primary completion | 2026-04-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-03 | actual | The whole study's end, after follow-up |
| First posted | 2025-01-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Forehead Lines
Interventions
- Drug: OnabotulinumtoxinA
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants who Achieve 'None' or 'Mild' on Facial Wrinkle Scale with Asian Photonumeric Guide (FWS-A) According to the Investigator Assessment of Forehead Lines (FHL) Severity at Maximum Contraction
measured Day 30
Number of Participants with Adverse Events (AEs)
measured Up to approximately 12 months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed